





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Figure 1





Sequences 1-40 (some did not sequence) panning 3 expts 1

His Thr Thr Val Tyr Gly Ala Gly
CAT ACG ACT GTT TAT GGG GCT GGT

Thr Glu Thr Pro Tyr Pro Thr Gly
ACT GAG ACG CCT TAT CCT ACT GGT

Leu Thr Thr Pro Phe Ser Ser Gly
CTT ACT ACT CCG TTT TCG TCG GGT

Gly Val Pro Leu Thr Met Asp Gly
GGT GTG CCT CTT ACG ATG GAT GGT

Lys Leu Pro Thr Val Leu Arg Gly
AAG CTT CCG ACT GTT CTG CCG GGT

Cys Arg Phe His Gly Asn Arg Gly
TGT CGC TTT CAT GGG AAT CGT GGT

Tyr Thr Arg Asp Phe Glu Ala Gly
TAT ACT CGG GAT TTT GAG GCT GGT

Ser Ser Ala Ala Gly Pro Arg Gly
TCG TCG GCG GCT GGT CCG CGG GGT

Ser Leu Ile Gln Tyr Ser Arg Gly
TCT CTG ATT CAG TAT TCG AGG GGT

Asp Ala Leu Met Trp Pro UKN Gly
GAT GCT CTT ATG TGG CCT NTG GGT

Ser Ser UKN Ser Leu Tyr Ile Gly
TCG TCT CNT TCG TTG TAT ATT GGT

Phe Asn Thr Ser Thr Arg Thr Gly
TTT AAT ACT TCG ACG CGT ACG GGT

Thr Val Gln His Val Ala Phe Gly
ACT GTG CAG CAT GTT GCT TTT GGT

Asp Tyr Ser Phe Pro Pro Leu Gly
GAT TAT TCT TTT CCG CCT CTT GGT

Val Gly Ser Met Glu Ser Leu Gly
GTG GGG TCT ATG GAG TCG TTG GGT

Phe UKN Pro Met Ile UKN Ser Gly
TTT CAN CCG ATG ATT NGN TCG GGT

Ala Pro Pro Arg Val Thr Met Gly
GCG CCT CCG CGG GTT ACT ATG GGT

FIGURE 1H.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Ile Ala Thr Lys Thr Pro Lys Gly
ATT GCT ACG AAG ACG CCT AAG GGT

Lys Pro Pro Leu Phe Gln Ile Gly
AAG CCT CCG TTG TTT CAG ATT GGT

Tyr His Thr Ala His Asn Met Gly
TAT CAT ACT GCT CAT AAT ATG GGT

Ser Tyr Ile Gln Ala Thr His Gly
TCT TAT ATT CAG GCT ACG CAT GGT

Ser Ser Phe Ala Thr Phe Leu Gly
TCG TCT TTT GCT ACT TTT CTT GGT

Thr Thr Pro Pro Asn Phe Ala Gly
ACG ACT CCG CCG AAT TTT GCG GGT

Ile Ser Leu Asp Pro Arg Met Gly
ATT TCT CTT GAT CCG CGT ATG GGT

Ser Leu Pro Leu Phe Gly Ala Gly
TCG CTG CCG CTG TTT GGT GCG GGT

Asn Leu Leu Lys Thr Thr Leu Gly
AAT CTT CTT AAG ACT ACG CTT GGT

Asp Gln Asn Leu Pro Arg Arg Gly
GAT CAG AAT CTG CCG CGG CGG GGT

Ser His Phe Glu Gln Leu Leu Gly
AGT CAT TTT GAG CAG CTG CTT GGT

Thr Pro Gln Leu His His Gly Gly
ACG CCG CAG CTT CAT CAT GGT GGT

Ala Pro Leu Asp Arg Ile Thr Gly
GCG CCT CTG GAT AGG ATT ACG GGT

Phe Ala Pro Leu Ile Ala His Gly
TTT GCG CCT CTT ATT GCG CAT GGT


Ser Trp Ile TER Thr Phe Met Gly
TCG TGG ATT TAG ACG TTT ATG GGT

Asn Thr Trp Pro His Met Tyr Gly
AAT ACT TGG CCT CAT ATG TAT GGT

Glu Pro Leu Pro Thr Thr Leu Gly
GAG CCT CTT CCG ACT ACG TTG GGT


His Gly Pro His Leu Phe Asn Gly
CAT GGG CCT CAT CTG TTT AAT GGT


1 H (cont.)



His Leu His Ser Pro Ser Gly Gly
CAT CTT CAT AGT CCG TCG GGG GGT

1 H (cont)





Val Ala Phe Thr Arg Leu Pro Gly
GTG GCG TTT ACG CGG CTT CCG GGT

FIGURE 2H.



Patent & Trademark Office

Figure 3A






Figure 3B





EL4 cells pulsed with OVA peptide





Figure 4B






Figure 5A





Figure 5B





Patent & Trademark Office

Figure 6A

EL4 cells pulsed with OVA peptide






Figure 6B


EL4 cells only





Effector: Target Ratio	Single Immunization (%)	Double Immunization (Squares) (%)	Double Immunization (Diamonds) (%)
1	0	0	0
2	0	0	0
3	0	0	2
7	6	11	6
13	13	22	8
27	25	40	16
53	44	54	28
107	48	56	-
214	48	63	-

FIGURE 7



MSJ









FIGURE 8B





Condition	Days (approx.)
OVA peptide	2.5
Titermax + OVA	13
Hsp70 + OVA	11.5
Hsp70 + OVA-BiP	25.5

FIGURE 8(H)





Figure 9A





FIGURE 9B








FIGURE 9C.



Figure 9D.



19-aminohexylamino HA




FIGURE 10 A-B






FIGURE 10 c-d








FIGURE 10 E-F

E.



F.





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

FIGURE 11 A+B







FIGURE 11C-D.

C



D








FIGURE 12.





FIGURE 13 A

FIGURE 13B





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100





FIGURE 14A

1416




FIGURE 14B








FIGURE 15.



Fully Protected Peptide

peptide with terminal amine free

20% piperidine
DMF, 20 min., rt


50% TFA
CH₂Cl₂

20% piperidine
DMF, 30 min., rt


a) PyBop (2.5 eq.), DIPEA
DMF, rt, 5 min.

b) peptide with terminal amine free


FIGURE 16B




GDM, DMSO, rt, Dark, 4-5 hours




1) 1% TFA, CH₂Cl₂
 2) Pyridine, methanol (1:9)
 3) silica gel chromatography



a) 50% TFA, 40% CH₂Cl₂, 10% TIPS
 b) Purification










FIGURE 17B.



The image displays several chemical structures of linker systems used in antibody-drug conjugates. These structures are organized into three main columns, each representing a different type of linker: 'Cleavable temporary linker', 'Cleavable linker', and 'Photochemically cleavable linker'.

- Cleavable temporary linker:** This column shows two structures. The top structure features a complex polycyclic aromatic system with multiple methoxy and methyl substituents, connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group. The bottom structure shows a similar polycyclic aromatic system connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group, with a 'Cleavable temporary linker' label pointing to the amide bond.
- Cleavable linker:** This column shows two structures. The top structure features a complex polycyclic aromatic system with multiple methoxy and methyl substituents, connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group. The bottom structure shows a similar polycyclic aromatic system connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group, with a 'Cleavable linker' label pointing to the amide bond.
- Photochemically cleavable linker:** This column shows two structures. The top structure features a complex polycyclic aromatic system with multiple methoxy and methyl substituents, connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group. The bottom structure shows a similar polycyclic aromatic system connected via an amide bond to a linker containing a hydroxyl group and a carboxylic acid group, with a 'Photochemically cleavable linker' label pointing to the amide bond.

FIGURE 18




FIGURE 19 A-E





Figure 19 F.

Survival ratio of mice immunized 7 days before challenge with melanoma cells



Survival ratio of mice immunized 7 & 14 days after challenge with melanoma cells




FIGURE 19G.

